Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/sj.bdj.2017.305 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims Data.
Drugs Real World Outcomes
January 2025
Takeda Pharmaceuticals USA, Inc., 45 Hayden Avenue, Lexington, MA, 02421, USA.
Background: Lanadelumab is the only long-term prophylaxis indicated for reduced administration frequency in patients with hereditary angioedema who have been well controlled for > 6 months. Understanding the characteristics of patients who reduce administration frequency will help identify populations where frequency modifications may be appropriate.
Objective: We aimed to describe characteristics of patients who did and did not reduce lanadelumab administration frequency to inform real-world dosing regimens, and characteristics indicative of sustained frequency reduction.
Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study.
EClinicalMedicine
January 2025
Leicester Real World Evidence Unit, Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, LE5 4PW, UK.
Background: People with diabetes are at increased risk of hospitalisation, morbidity, and mortality following SARS-CoV-2 infection. Long-term outcomes for people with diabetes previously hospitalised with COVID-19 are, however, unknown. This study aimed to determine the longer-term physical and mental health effects of COVID-19 in people with and without diabetes.
View Article and Find Full Text PDFMontreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy.
Front Neurol
December 2024
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Background: The Montreal Cognitive assessment (MoCA) is a well-validated global cognitive screening instrument. Its validity in progressive supranuclear palsy (PSP) has not been assessed.
Objectives: To evaluate the MoCA as an outcome measure in PSP clinical trials.
Commentary on "Protecting User Privacy and Rights in Academic Data-Sharing Partnerships: Principles From a Pilot Program at Crisis Text Line".
J Med Internet Res
December 2024
Yakima, WA, United States.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!